This study evaluated the in vitro interaction between ciprofloxacin (CIP) and classical antifungals against Histoplasma capsulatum var. capsulatum in mycelial (n = 16) and yeast-like forms (n = 9) and Coccidioides posadasii in mycelial form (n = 16). This research was conducted through broth microdilution and macrodilution, according to Clinical Laboratory Standards Institute. Inocula were prepared to obtain from 0.5 · 10 3 to 2.5 · 10 4 cfu ml )1 for H. capsulatum and from 10 3 to 5 · 10 3 cfu ml
Introduction
Classical histoplasmosis and coccidioidomycosis are deep mycoses endemic to the American continent, especially in the United States, Mexico and Brazil, which are caused by the dimorphic fungi Histoplasma capsulatum var. capsulatum and Coccidioides spp. respectively. In Brazil, coccidioidomycosis is found only in the Northeast region, caused by the species C. posadasii, while histoplasmosis is diagnosed all over the country, with a mortality rate of 40%, when associated with AIDS. 1, 2 The treatment of these diseases consists of azoles in cases of mild to moderate symptoms and amphotericin B (AMB) in severe cases. 2, 3 Although common antifungal therapies are efficient to treat these mycoses, refractory cases and relapses have been described in patients with disseminated disease.
2,4-6 Therefore, the pursuit of new therapeutic strategies against these pathogens has become more relevant.
Ciprofloxacin (CIP) is an antimicrobial drug of the fluoroquinolone group that inhibits the activity of the enzymes DNA gyrase and topoisomerase IV, which are essential for the replication and transcription of bacterial DNA. Studies found that quinolones may also act on topoisomerase II of fungi, potentially showing an antifungal effect. 7, 8 Based on this context, this research evaluated the in vitro interaction between CIP and AMB, itraconazole (ITC), voriconazole (VRC) or caspofungin (CAS) against H. capsulatum and C. posadasii.
Materials and methods
For such, H. capsulatum isolates in mycelial (n = 16) and yeast-like forms (n = 9), and C. posadasii in mycelial form (n = 16) from the culture collection of the Specialized Medical Mycology Center of the Federal University of Ceará, were included in this study. The strains were handled within a class II biosafety cabinet, in a biosafety level three laboratory.
Stock solutions of AMB (Sigma Chemical Corporation, St. Louis, MO, USA), ITC (Janssen Pharmaceutica, Beerse, Belgium) and VRC (Pfizer Pharmaceuticals, New York, NY, USA) were diluted with dimethyl sulfoxide (DMSO) and CAS (Merck Sharp & Dohme, São Paulo, Brazil) was diluted with distilled water. CIP (Fresenius Kabi, São Paulo, Brazil) was used as water solution at 2000 lg ml )1 . All solutions were stored at )20°C, until the moment of use. Serial dilutions of each antimicrobial agent were prepared with RPMI 1640 (Sigma Chemical Corporation), supplemented with Lglutamine, buffered at a pH of 7.0 with MOPS 165 mmol l )1 (Sigma Chemical Corporation).
Inocula of H. capsulatum in the mycelial form and C. posadasii were prepared after growing the strains in the mycelial phase for 7 days at 28°C. Sterile saline was added to each culture tube, the mycelial surface was scraped with a swab and the content was transferred to a sterile tube, where the turbidity was adjusted through spectrophotometry, at 530 nm, to 95% of transmittance. As for the isolates of H. capsulatum in the yeast-like form, they were obtained through growth on Brain and Heart Infusion agar supplemented with sheep blood (10%), at 35°C, and maintained through weekly passages. To prepare the fungal inoculum, a fragment of the colony of H. capsulatum in the yeast-like form was diluted in sterile saline and the turbidity was adjusted through spectrophotometry, as previously described. Afterwards, the fungal suspensions were diluted to obtain inocula ranging from 0.5 · 10 3 to 2.5 · 10 4 cfu ml )1 for H.
capsulatum in both forms and from 10 3 to 5 · 10 3 cfu ml )1 for C. posadasii in the mycelial form. 3, 9 Susceptibility tests were carried out as described by Brilhante et al. [9] for H. capsulatum and Cordeiro et al. [3] for C. posadasii. Initially, minimum inhibitory concentration (MIC) for each drug alone was determined. MICs were defined as the lowest concentration that caused 100% of fungal growth inhibition for amphotericin B and 80% of inhibition for the other drugs. Then, these MICs were used as the highest concentration for each drug during combination assays. The concentration range for each drug when combined was CIP (0.488-250 lg ml ) and CAS (0.00097-2 lg ml ). As for C. posadasii in mycelial form, the concentration ranges were CIP (3.125-50 lg ml ). The procedures were performed in duplicate. The results were read visually after 2 days of incubation at 35°C for C. posadasii in mycelial form, 4 days for H. capsulatum in yeast-like form and 7 days for H. capsulatum in mycelial form.
The interaction between low concentrations of CIP (LowCIP) and AMB within the previously described concentration range was also evaluated, 10 using the following intervals of concentration for CIP: 0.0195-10 lg ml )1 against H. capsulatum and 0.625-10 lg ml )1 against C. posadasii, both in mycelial form.
For all combination assays, MICs were defined as the lowest concentration capable of inhibiting 80% of visible fungal growth, when compared to the drug-free control. 3, 9 The effect of CIP on antifungal MICs was evaluated by paired sample t-Student test. The results were expressed as mean values and P-values lower than 0.05 were considered significant. In addition, drug interaction was evaluated by calculating the fractional inhibitory concentration index (FICI), which was classified as synergistic (FICI £ 0.5), indifferent (0.5 < FICI < 4) or antagonistic (FICI ‡ 4) for each combination tested against H. capsulatum and C. posadasii.
11 Afterwards, the obtained FICI values were compared through Wilcoxon test (P < 0.05). Four American Type Culture Collection (ATCC) type strains (Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258, Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922) were included as drug control.
Results
Ciprofloxacin alone inhibited 8 ⁄ 9 strains of H. capsulatum in the yeast-like form (62.5 < MIC < 250 lg ml )1 ), but it was ineffective against H. capsulatum and C. posadasii in the mycelial form. Thus, the highest CIP concentration tested against these fungi was also used as the highest concentration for the combination assays. Statistical analyses revealed significant antifungal MIC reductions for all combinations of CIP with antifungal drugs against the strains of C. posadasii in the mycelial phase (CIP ⁄ AMB: P = 0.0011; CIP ⁄ ITC: P = 0.0001; CIP ⁄ VRC: P = 0.0000; CIP ⁄ CAS: P = 0.0000) and H. capsulatum in the mycelial phase (CIP ⁄ AMB: P = 0.0006; CIP ⁄ ITC: P = 0.0000; CIP ⁄ VRC: P = 0.0000; CIP ⁄ CAS: P = 0.0001). Significant antifungal MIC reductions were also observed against H. capsulatum in yeast-like phase (CIP ⁄ AMB: P = 0.0499; CIP ⁄ ITC: P = 0.0016; CIP ⁄ CAS: P = 0.0063), except for the combination of CIP and VRC (P = 0.1720) ( Table 1) .
For the combination of low ciprofloxacin concentrations with AMB, MICs for AMB were significantly smaller against the strains of C. posadasii (P = 0.0000), but not against those of H. capsulatum (P = 0.1728) ( Table 1) .
When evaluating the interaction between CIP and antifungal drugs, it was possible to verify that the main synergistic interactions were observed when combining CIP and ITC (14 ⁄ 16 strains; 0.02 £ FICI £ 0.37), CIP and VRC (16 ⁄ 16 strains; 0.18 £ FICI £ 0.37), or CIP and CAS (9 ⁄ 16 strains; 0.01 £ FICI £ 0.37) against H. capsulatum in mycelial form, for which values of FICI were significantly smaller than those for CIP and AMB (6 ⁄ 16 strains; 0.18 £ FICI £ 0.37) (ITC P = 0.0073; VRC P = 0.0051; CAS P = 0.0458). As for C. posadasii, synergistic interactions were observed for the combinations between CIP and ITC (13 ⁄ 16 strains; 0.09 £ FICI £ 0.37), CIP and VRC (13 ⁄ 16 strains; 0.09 £ FICI £ 0.37) or CIP and CAS (14 ⁄ 16 strains; 0.09 £ FICI £ 0.37), whose FICI values were also significantly smaller than those for CIP and AMB (3 ⁄ 16 strains; FICI = 0.37) (ITC P = 0.0088; VRC P = 0.0014; CAS P = 0.0073). Even the combinations that were not synergistic exhibited significant MIC reductions, and no antagonistic interactions were observed.
Standard strains used as drug controls, showed MIC values within the range recommended by the Clinical Laboratory Standards Institute: C. parapsilosis ATCC 22019 (AMB: 1 lg ml )1 ; ITC: 0.5 lg ml
; VRC: 0.0312 lg ml )1 ; CAS: 0.5 lg ml ); S. aureus ATCC 29213 (CIP: 0.12 lg ml )1 ) and E. coli ATCC 25922
(CIP: 0.004 lg ml )1 ). 
Discussion
Quinolones have been shown to improve in vitro effects of antifungal drugs against yeast and mould species. 8, [12] [13] [14] In addition, the association of CIP and fluconazole was shown effective in treating invasive candidiasis and pulmonary mucormycosis in murine models. 15 However, the combination of CIP and classical antifungals has never been tested in vitro nor in vivo against dimorphic fungi.
Although typically not presenting antifungal activity, CIP could bind to fungal topoisomerase II, 10 possibly inhibiting DNA replication. This is only observed when CIP is associated with antifungals, probably because certain antimycotics alter fungal membrane permeability, increasing intracellular levels of this quinolone. 16 In addition, it has been suggested that CIP enhances the activity of azoles by overlapping substrate specificity of the ATP-binding cassette transporters (efflux pumps), which results in higher intracellular concentrations of these antifungal agents. 10 These facts could explain the effective interaction between CIP and azoles observed in this study. MICs of VRC alone against yeast-like form of H. capsulatum were already very low, suggesting that VRC molecules were not suffering the effects of effluxpump activity, reaching the maximum intracellular concentration within the yeast cell. Hence, considering the possible effects of CIP on efflux pumps, the combination of CIP with VRC did not result in antifungal MIC reduction.
It has also been suggested that CIP may increase the susceptibility of (1.3)-b-D-glucan synthase to echinocandins, 10 which possibly explains the effective interaction between CIP and CAS against H. capsulatum and C. posadasii, even though echinocandins alone are not effective against the former. In this study, it was observed that the combination of CIP with AMB resulted in antifungal MIC reduction, corroborating the results of Sugar et al. [12] who showed that this drug combination provided significantly more protection to mice infected with Candida albicans, when compared to AMB or CIP alone. In addition, it was observed that LowCIP also significantly reduced the MIC of AMB against C. posadasii. This dosedependent interaction between AMB and CIP has been demonstrated against C. albicans and Aspergillus fumigatus. 10 It has been shown that LowCIP seem to increase AMB-induced pore formation on fungal cell membranes, producing a synergistic effect, while high concentrations may produce antagonistic effects. 10 In conclusion, the data from this study suggest new alternatives for the treatment of histoplasmosis and coccidioidomycosis, suggesting that CIP should behave as an adjuvant agent when added to the antifungal therapy, providing perspectives to delineate in vivo studies.
